Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.49 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.47 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.47 |
| ▸ | MME | P08473 | 10/20 | 0.46 |
| ▸ | ACE | P12821 | 8/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21572784 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL1908566 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL18059572 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL18059571 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL597164 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL24404055 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL18574633 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL598890 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| Hydrochloric Acid SCHEMBL597844 | 0.99 | GPR88 (0.48) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL7426879 | 0.99 | GPR88 (0.48) | GPR88SRRPSAT1MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3611160-B1 | AMMONIUM CARBOXYLATE COMPOUND, CRYSTAL FORM AND AMORPHOUS SUBSTANCE THEREOF, AND PREPARATION METHOD THEREFOR | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2023-03-29 | — | — | EP | disclosed |
| US-11434192-B2 | Process and intermediates | NOVARTIS AG (CH) | 2022-09-06 | — | — | US | disclosed |
| US-11318116-B2 | Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof | LAURUS LABS LIMITED (IN) | 2022-05-03 | — | — | US | disclosed |
| US-11161803-B2 | Ammonium carboxylate compound, crystalline form, amorphous form and preparation method thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2021-11-02 | — | — | US | disclosed |
| US-20210046050-A1 | STABLE AMORPHOUS FORM OF SACUBITRIL VALSARTAN TRISODIUM COMPLEX AND PROCESSES FOR PREPARATION THEREOF | LAURUS LABS LTD (IN) | 2021-02-18 | — | — | US | disclosed |
| EP-3386955-B1 | INTERMEDIATES FOR THE PREPARATION OF SACUBITRIL AND THEIR PREPARATION | NOVARTIS AG (CH) | 2020-08-05 | — | — | EP | disclosed |
| US-20200055812-A1 | AMMONIUM CARBOXYLATE COMPOUND, CRYSTALLINE FORM, AMORPHOUS FORM AND PREPARATION METHOD THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2020-02-20 | — | — | US | disclosed |
| EP-3611160-A1 | AMMONIUM CARBOXYLATE COMPOUND, CRYSTAL FORM AND AMORPHOUS SUBSTANCE THEREOF, AND PREPARATION METHOD THEREFOR | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2020-02-19 | — | — | EP | disclosed |
| US-20190308927-A1 | PROCESS AND INTERMEDIATES | NOVARTIS PHARMA AG (CH) | 2019-10-10 | — | — | US | disclosed |
| US-20190308927-A1 | PROCESS AND INTERMEDIATES | NOVARTIS PHARMA AG (CH) | 2019-10-10 | — | — | US | disclosed |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| WO-2008083967-A2 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2008-07-17 | — | — | WO | disclosed |
| US-5354892-A | Treating cardiovascular disorders; endopeptidase inhibitors; diuretics | CIBA-GEIGY CORPORATION (US) | 1994-10-11 | — | — | US | disclosed |
| EP-0555175-A1 | Biaryl substituted 4-amino-butyric acid amides | CIBA-GEIGY AG (CH) | 1993-08-11 | — | — | EP | disclosed |
| US-5217996-A | Endopeptidase inhibitors | CIBA-GEIGY CORPORATION (US) | 1993-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318116-B2 | Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof | AGT, ACE, REN | GPR88 3416/4885SRR 305/4885PSAT1 1684/4885 |
| US-20190308927-A1 | PROCESS AND INTERMEDIATES | MME, ACE, DNPEP | GPR88 2700/4885SRR 496/4885PSAT1 214/4885 |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | MME, REN, PAH | GPR88 2050/4885SRR 911/4885PSAT1 2304/4885 |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | MME, REN, PAH | GPR88 2050/4885SRR 911/4885PSAT1 2304/4885 |
| US-11161803-B2 | Ammonium carboxylate compound, crystalline form, amorphous form and preparation method thereof | ACMSD, ADSL, AMD1 | GPR88 4222/4885SRR 2463/4885PSAT1 1695/4885 |
| US-20200055812-A1 | AMMONIUM CARBOXYLATE COMPOUND, CRYSTALLINE FORM, AMORPHOUS FORM AND PREPARATION METHOD THEREOF | ACMSD, ADSL, AMD1 | GPR88 4222/4885SRR 2463/4885PSAT1 1695/4885 |
| US-20210046050-A1 | STABLE AMORPHOUS FORM OF SACUBITRIL VALSARTAN TRISODIUM COMPLEX AND PROCESSES FOR PREPARATION THEREOF | AGT, ACE, REN | GPR88 3416/4885SRR 305/4885PSAT1 1684/4885 |
| US-11434192-B2 | Process and intermediates | MME, ACE, DNPEP | GPR88 2700/4885SRR 496/4885PSAT1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.